Marie T. Baccara-Dinet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marie T. Baccara-Dinet has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andriy Cherkas
Sanofi, Frankfurt am Main, Germany
1 shared publication Baerbel Rotthaeuser
Sanofi Frankfurt Germany
1 shared publicationBaptiste Berthou
Biostatistician, IT&M Stats for Sanofi Neuilly‐sur‐Seine France
1 shared publicationDaniel Gipe
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA
1 shared publication- Eric Bruckert
Department of Endocrinology and Cardiovascular Disease Prevention, Assistance Publique-Hôpitaux de Paris, La Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
1 shared publication - Felix Reschke
Centre for Diabetes and Endocrinology Children's Hospital Auf der Bult Hannover Germany
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6584-6594
A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes ( FABULINUS ): Rationale and Study Design
Introduction: Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of various immune‐mediated conditions. Methods and Analysis: This is a double‐blind, Phase 2 trial to assess the efficacy and safety of frexalimab for preservation of pancreatic β‐cell function in adolescents and young adults (12–35 years) with recently diagnosed Stage 3 T1D on insulin therapy. Participants who meet all inclusion criteria will be randomly assigned to receive frexalimab or a matching placebo in a 2:1 ratio in all cohorts for 104 weeks. A total of 192 participants will be recruited sequentially into two parts. Part A ( n = 30) is exploratory and designed to establish the safety of the highest dose of frexalimab compared with placebo in adults (18–35 years). In Part B, 162 adolescents and young adults (12–21 years) are randomised sequentially to three age‐adjusted dose‐levels of frexalimab or placebo. The primary endpoint is the change from baseline to 52 weeks in mean 2‐h mixed meal tolerance test stimulated C‐peptide concentration, calculated from the area under the curve. Secondary endpoints include time in range by intermittent continuous glucose monitoring measures, glycated haemoglobin (HbA1c), daily insulin dose, number of hypoglycaemic events and insulin dose adjusted HbA1c measurements. Ethics and Dissemination: This trial received ethical approval in October 2023 and began screening in December 2023 with first participant randomised in January 2024. The results will be submitted to a peer‐reviewed medical journal and presented at conferences. Trial registration: EU trial number: 2022‐500531‐36‐00 and ClinicalTrials.gov : NCT06111586
- 27 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6584-6594
Open AccessA Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes ( FABULINUS ): Rationale and Study Design
Introduction: Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of various immune‐mediated conditions. Methods and Analysis: This is a double‐blind, Phase 2 trial to assess the efficacy and safety of frexalimab for preservation of pancreatic β‐cell function in adolescents and young adults (12–35 years) with recently diagnosed Stage 3 T1D on insulin therapy. Participants who meet all inclusion criteria will be randomly assigned to receive frexalimab or a matching placebo in a 2:1 ratio in all cohorts for 104 weeks. A total of 192 participants will be recruited sequentially into two parts. Part A ( n = 30) is exploratory and designed to establish the safety of the highest dose of frexalimab compared with placebo in adults (18–35 years). In Part B, 162 adolescents and young adults (12–21 years) are randomised sequentially to three age‐adjusted dose‐levels of frexalimab or placebo. The primary endpoint is the change from baseline to 52 weeks in mean 2‐h mixed meal tolerance test stimulated C‐peptide concentration, calculated from the area under the curve. Secondary endpoints include time in range by intermittent continuous glucose monitoring measures, glycated haemoglobin (HbA1c), daily insulin dose, number of hypoglycaemic events and insulin dose adjusted HbA1c measurements. Ethics and Dissemination: This trial received ethical approval in October 2023 and began screening in December 2023 with first participant randomised in January 2024. The results will be submitted to a peer‐reviewed medical journal and presented at conferences. Trial registration: EU trial number: 2022‐500531‐36‐00 and ClinicalTrials.gov : NCT06111586
- Open Access
- 1 November 2014
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 8 (6) , 554-561
Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial
- 1 November 2014
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 8 (6) , 554-561
Open AccessEfficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial